Zelluna plans to initiate the first clinical trial of ZI-MA4-1 subject to regulatory approval (CTA approval), marking a key milestone in the clinical development of the company's off-the-shelf TCR-NK ...
2022—Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T ...
A patient with progressive metastatic pancreatic cancer was treated with a single infusion of 16.2×10 9 autologous T cells that had been genetically engineered to clonally express two allogeneic HLA-C ...
The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...
T cells are a critical part of the adaptive immune system that respond to pathogens, tumors, or play a key role in autoimmune diseases. A T cell recognizes potential targets through its T cell ...
Fourth Quarter 2025 Key Regulatory Milestone Achieved With CTA Submission. Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf T Cell Receptor-based Natural Ki ...
Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...
Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results